RAFAEL HOLDINGS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-04-30 was $33.00K, a 10.00% increase year-over-year.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-01-31 was $27.00K, a 37.21% decline year-over-year.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-10-31 was $48.00K, a 23.08% increase year-over-year.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-07-31 was $24.00K, a 31.43% decline year-over-year.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $136.00K, a 37.61% decline from fiscal 2023.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $218.00K, a 190.67% increase from fiscal 2022.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $75.00K, a 59.46% decline from fiscal 2021.
- RAFAEL HOLDINGS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2021 was $185.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-04-30 | $33.00K 10-Q · filed 2025-06-11 | $132.00K derived: sum of 4 quarters · filed 2025-06-11 |
| 2025-01-31 | $27.00K 10-Q · filed 2025-03-14 | $129.00K derived: sum of 4 quarters · filed 2025-06-11 |
| 2024-10-31 | $48.00K 10-Q · filed 2024-12-11 | $145.00K derived: sum of 4 quarters · filed 2025-06-11 |
| 2024-07-31 | $24.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $136.00K 10-K/A · filed 2024-12-20 |
| 2024-04-30 | $30.00K 10-Q · filed 2025-06-11 | $147.00K derived: sum of 4 quarters · filed 2025-06-11 |
| 2024-01-31 | $43.00K 10-Q · filed 2025-03-14 | $143.00K derived: sum of 4 quarters · filed 2025-03-14 |
| 2023-10-31 | $39.00K 10-Q · filed 2024-12-11 | $251.00K derived: sum of 4 quarters · filed 2024-12-20 |
| 2023-07-31 | $35.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | $218.00K 10-K/A · filed 2024-12-20 |
| 2023-04-30 | $26.00K 10-Q · filed 2024-06-14 | $186.00K derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | $151.00K 10-Q · filed 2024-03-14 | $161.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-10-31 | $6.00K 10-Q · filed 2023-12-14 | $51.00K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | $75.00K 10-K · filed 2023-10-30 |
| 2022-04-30 | $1.00K 10-Q · filed 2023-06-13 | $72.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-01-31 | $41.00K 10-Q · filed 2023-03-14 | $110.00K derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-10-31 | $30.00K 10-Q · filed 2022-12-13 | $215.00K derived: sum of 4 quarters · filed 2022-12-13 |
| 2021-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $185.00K 10-K · filed 2022-10-31 |
| 2021-04-30 | $39.00K 10-Q · filed 2022-06-14 | |
| 2021-01-31 | $146.00K 10-Q · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |